Home › Interstitial Lung Diseases › Minnesota
Interstitial Lung Diseases clinical trials in Minnesota
15 studies for Interstitial Lung Diseases are looking for participants at sites in Minnesota.
Cities in Minnesota
LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- University of Minnesota, Minneapolis
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 29, 2026 · NCT05798923FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
- University of Minnesota, Minneapolis
- Mayo Clinic, Rochester, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07540988A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
- University of Minnesota, Minneapolis
- Mayo Clinic, Rochester, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06806592A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis
- University of Minnesota, Minneapolis
RecruitingPhase 3
Ages 40 and older · All sexes · Updated Sep 8, 2026 · NCT07201922Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- University of Minnesota, Minneapolis
Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06911632DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Mayo Clinic - Rochester, Rochester
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06388421Platform Clinical Study for Conquering Scleroderma
- Mayo Clinic, Rochester
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06195072RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
- Mayo Clinic Rochester, Rochester
RecruitingPhase 2/3
Ages 18 to 75 · All sexes · Updated Aug 17, 2026 · NCT06328777Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- University of Minnesota, Minneapolis
RecruitingObservational study
Ages 21 and older · All sexes · Updated Aug 12, 2026 · NCT01915511Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease
- Mayo Clinic, Rochester
RecruitingPhase 2
Ages 4 and older · All sexes · Updated Jul 22, 2026 · NCT04925375Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- University of Minnesota Health Clinical Research Unit (CRU), Minneapolis
- Mayo Clinic, Rochester
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05943535TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
- University of Minnesota, Minneapolis
RecruitingObservational study
Up to age 24 · All sexes · Updated Jun 22, 2026 · NCT04098445Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
- Mayo Clinic, Rochester
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Apr 29, 2026 · NCT03478826Home-based Pulmonary Rehabilitation and Health Coaching in Patients With Fibrotic Interstitial Lung Disease
- University of Minnesota, Minneapolis
- Mayo Clinic in Rochester, Rochester
Recruiting
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT06751069Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough
- Mayo Clinic in Rochester, Rochester
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Jan 21, 2026 · NCT05120934From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.